Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Part 1：r/r B-cell Malignancies × orelabrutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, B-Cell, Marginal Zone 14 Lymphoma, Mantle-Cell 10 Lymphoma, Large B-Cell, Diffuse 8 Lymphoma 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Recurrence 1 Part 1：r/r B-cell Malignancies 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Hematologic Neoplasms 1

Interventions

orelabrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04014205 2023-04-18

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 1/2 Unknown

Part 1：r/r B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡